🇺🇸 FDA
Patent

US 9060971

Combination pharmaceutical agents as inhibitors of HCV replication

granted A61KA61K31/13A61K31/4184

Quick answer

US patent 9060971 (Combination pharmaceutical agents as inhibitors of HCV replication) held by Enanta Pharmaceuticals, Inc. expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Jun 23 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/13, A61K31/4184, A61K31/4196, A61K31/437